These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 34503964)
41. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer. Jin P; Bai M; Liu J; Yu J; Meng X Front Immunol; 2022; 13():1004351. PubMed ID: 36341372 [TBL] [Abstract][Full Text] [Related]
42. Synthesis and Biologic Evaluation of a Novel Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984 [TBL] [Abstract][Full Text] [Related]
44. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma]. Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381 [TBL] [Abstract][Full Text] [Related]
45. PET imaging of an optimized anti-PD-L1 probe Zhou H; Bao G; Wang Z; Zhang B; Li D; Chen L; Deng X; Yu B; Zhao J; Zhu X EJNMMI Res; 2022 Jun; 12(1):35. PubMed ID: 35695985 [TBL] [Abstract][Full Text] [Related]
46. In Vivo Imaging of the Programmed Death Ligand 1 by González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151 [TBL] [Abstract][Full Text] [Related]
47. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739 [TBL] [Abstract][Full Text] [Related]
48. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging. Miao Y; Lv G; Chen Y; Qiu L; Xie M; Lin J Bioorg Med Chem Lett; 2020 Dec; 30(24):127572. PubMed ID: 32979488 [TBL] [Abstract][Full Text] [Related]
49. Preclinical and first-in-human evaluation of Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714 [TBL] [Abstract][Full Text] [Related]
50. Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549 [TBL] [Abstract][Full Text] [Related]
51. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500 [TBL] [Abstract][Full Text] [Related]
52. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
53. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367 [TBL] [Abstract][Full Text] [Related]
54. Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative de Heer EC; Brouwers AH; Boellaard R; Sluiter WJ; Diercks GFH; Hospers GAP; de Vries EGE; Jalving M EJNMMI Res; 2018 Nov; 8(1):101. PubMed ID: 30460579 [TBL] [Abstract][Full Text] [Related]
55. Prognostic value of total metabolic tumour volume and therapy-response assessment by [ Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873 [TBL] [Abstract][Full Text] [Related]
56. Development, Characterization, and Radiation Dosimetry Studies of Kim J; Donnelly DJ; Tran T; Pena A; Shorts AO; Petrone TV; Zhang Y; Boy KM; Scola PM; Tenney DJ; Poss MA; Soars MG; Bonacorsi SJ; Cole EL; Grootendorst DJ; Chow PL; Meanwell NA; Du S Mol Imaging Biol; 2024 Apr; 26(2):301-309. PubMed ID: 38123744 [TBL] [Abstract][Full Text] [Related]
57. Value of Kaira K; Kuji I; Kagamu H Cancer Imaging; 2021 Jan; 21(1):11. PubMed ID: 33441183 [TBL] [Abstract][Full Text] [Related]
58. Uptake of Radium-223 Dichloride and Early [ Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074 [TBL] [Abstract][Full Text] [Related]
59. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148 [TBL] [Abstract][Full Text] [Related]
60. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Léger MA; Routy B; Juneau D Semin Nucl Med; 2022 Nov; 52(6):707-719. PubMed ID: 35636978 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]